Drug Profile
Research programme: kinase modulators - Carna Biosciences/RaQualia Pharma
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Carna Biosciences; RaQualia Pharma
- Class
- Mechanism of Action Phosphotransferase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in Japan
- 22 Mar 2013 Preclinical trials in Undefined indication in Japan (unspecified route)